FDA pushes back decisions on AbbVie's Rinvoq sNDAs to further review a failed Pfizer trial
Safety questions related to the lucrative class of medicines known as JAK inhibitors are continuing to slow the push to expand their labels.
AbbVie on Friday announced that the FDA said it will not meet its action dates for the sNDAs for its JAK inhibitor Rinvoq. The company is seeking to use the drug as a treatment of adults with active psoriatic arthritis and adults with active ankylosing spondylitis and did not say how long the delay will be.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,300+ biopharma pros reading Endpoints daily — and it's free.